Novavax, Inc. (NVAX)

Novavax Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	983.71	1,982	1,146	475.6	18.66
Revenue Growth (YoY)	-50.36%	72.89%	141.02%	2448.48%	-45.57%
Cost of Revenue	343.77	902.64	0	0	0
Gross Profit	639.94	1,079	1,146	475.6	18.66
Selling, General & Admin	468.95	488.69	298.36	145.29	34.42
Research & Development	737.5	1,235	2,535	747.03	113.84
Other Operating Expenses	0	0	0	0	-9.02
Operating Expenses	1,206	1,724	2,833	892.32	139.24
Operating Income	-566.51	-644.74	-1,686.58	-416.72	-120.58
Interest Expense / Income	14.42	19.88	21.13	15.15	13.61
Other Expense / Income	-37.9	-10.97	6.83	-13.61	-1.5
Pretax Income	-543.03	-653.65	-1,714.54	-418.26	-132.69
Income Tax	2.03	4.29	29.22	0	0
Net Income	-545.06	-657.94	-1,743.75	-418.26	-132.69
Shares Outstanding (Basic)	101	78	74	58	24
Shares Outstanding (Diluted)	101	78	74	58	24
Shares Change	28.89%	5.08%	29.27%	138.81%	30.35%
EPS (Basic)	-5.41	-8.42	-23.44	-7.27	-5.51
EPS (Diluted)	-5.41	-8.42	-23.44	-7.27	-5.51
Free Cash Flow	-772.77	-508.92	265.46	-97.16	-120.15
Free Cash Flow Per Share	-7.67	-6.51	3.57	-1.69	-4.99
Gross Margin	65.05%	54.46%	100.00%	100.00%	100.00%
Operating Margin	-57.59%	-32.53%	-147.13%	-87.62%	-646.13%
Profit Margin	-55.41%	-33.20%	-152.12%	-87.94%	-711.04%
Free Cash Flow Margin	-78.56%	-25.68%	23.16%	-20.43%	-643.81%
EBITDA	-487.39	-604.71	-1,680.75	-398.23	-113.41
EBITDA Margin	-49.55%	-30.51%	-146.63%	-83.73%	-607.68%
Depreciation & Amortization	41.23	29.05	12.66	4.89	5.68
EBIT	-528.62	-633.77	-1,693.41	-403.11	-119.08
EBIT Margin	-53.74%	-31.98%	-147.73%	-84.76%	-638.10%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).